Belgian 3D printing specialist Materialise has published its financial results for the second quarter of 2024. The company increased its turnover by 6.2% year-on-year to 68.8 million euros.
Growth in the medical technology sector is particularly noteworthy. Here, Materialise recorded an increase in turnover of 12.8% to EUR 28.1 million. The Software and Manufacturing segments also grew, albeit to a lesser extent.
Adjusted EBIT improved significantly from EUR -597,000 in the previous year to EUR 3.9 million. EBITDA rose from 4.8 to 9.2 million euros. Net profit amounted to 3.9 million euros, which corresponds to earnings per share of 0.07 euros.
Brigitte de Vet-Veithen, CEO of Materialise, expressed her satisfaction with the results: “Materialise continued its growth trajectory in the second quarter of 2024 and achieved record sales.” She emphasized that the company remained profitable despite intensified investments.
An important strategic step was the acquisition of the Belgian company FEops in July 2024. FEops develops AI-supported simulation technologies for structural heart interventions. Materialise aims to strengthen its position in the personalized treatment of heart disease.
The gross margin remained stable at 57%. Expenditure on research and development, sales and marketing and administration rose by 10.4% to EUR 36.6 million. This reflects the company’s increased investments.
Materialise’s liquidity remains solid. As at June 30, 2024, the company had cash and cash equivalents of EUR 125.5 million. The net cash position improved by EUR 4.3 million to EUR 67.5 million compared to the end of 2023.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
